Axitinib – Treatment for Advanced Renal Cell Carcinoma

Inlyta (axitinib) was developed by Pfizer for treating advanced renal cell carcinoma (ARCC) and hepatocellular carcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news